Systemic primary carnitine deficiency
(Redirected from Deficiency of plasma-membrane carnitine transporter)
Systemic Primary Carnitine Deficiency (SPCD), also known as Carnitine Uptake Defect or Carnitine Transporter Deficiency, is a rare genetic disorder that affects the body's ability to transport carnitine, a substance essential for the oxidation of long-chain fatty acids. This condition leads to a variety of symptoms, primarily affecting the muscles and heart, and can result in serious complications if not treated promptly.
Causes[edit | edit source]
SPCD is caused by mutations in the SLC22A5 gene, which encodes the organic cation transporter type 2 (OCTN2), responsible for the uptake of carnitine into cells. Without functional OCTN2, carnitine cannot be properly absorbed from the diet or conserved by the kidneys, leading to a systemic deficiency.
Symptoms[edit | edit source]
Symptoms of SPCD can vary widely among affected individuals but typically include muscle weakness, hypoglycemia (low blood sugar), cardiomyopathy (disease of the heart muscle), and hepatic encephalopathy (brain dysfunction caused by liver disease). Symptoms can appear anytime from infancy to adulthood, with some individuals remaining asymptomatic.
Diagnosis[edit | edit source]
Diagnosis of SPCD involves a combination of clinical evaluation, biochemical tests showing low plasma carnitine levels, and genetic testing confirming mutations in the SLC22A5 gene. Early diagnosis and treatment are crucial to prevent serious complications.
Treatment[edit | edit source]
The primary treatment for SPCD is oral L-carnitine supplementation, which can significantly improve symptoms and prevent metabolic crises. Patients may also require dietary modifications and management of symptoms related to complications.
Prognosis[edit | edit source]
With early diagnosis and appropriate treatment, individuals with SPCD can lead normal, healthy lives. However, untreated SPCD can result in severe metabolic crises, irreversible organ damage, and potentially fatal outcomes.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD